Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential
koto_feja Thesis I covered Gain Therapeutics, Inc. (NASDAQ:GANX) some months ago, having found both the company’s drug-discovery platform Magellan and drug candidate GT-02287, the second drug candidate with best-in-class potential which has been generated …